1Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immuno-regulation. Lancet 1981;17:839-842.
3Google Scholar3.McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-442.
4CrossRefMedlineGoogle Scholar4.Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-310.
5CrossRefMedlineWeb of ScienceGoogle Scholar5.?Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361.
6CrossRefMedlineWeb of ScienceGoogle Scholar6.?Brennan F, Jackson A, Chantry D, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;334:244-247.
7CrossRefGoogle Scholar7.?Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, Elliott M, et al. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 1993;11:173-175.
8Google Scholar8.?Van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-553.
9CrossRefMedlineWeb of ScienceGoogle Scholar9.?Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008;43:402-407.
10CrossRefMedlineWeb of ScienceGoogle Scholar10.Toy D, Miossec P. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006;177:36-39.
